Shingrix Dementia Prevention: New Research & Brain Protection!

If your family and friends have escaped dementia, you are among the lucky ones. Almost everyone I talk to knows someone who has experienced the challenges of cognitive decline. More than 7 million Americans are living with Alzheimer’s disease, and the number keeps climbing. For decades, scientists have focused on amyloid plaques as the chief villain in Alzheimer’s disease (AD), but expensive anti-amyloid drugs have delivered disappointing results for many patients. Now a surprising new line of research is pointing in a radically different direction. Shingrix dementia prevention may sound improbable at first, but a brand-new study published in Alzheimer’s & Dementia (April 28, 2026) adds important new evidence that the shingles vaccine could lower the risk of dementia, including both Alzheimer’s disease and vascular dementia.

That finding is stirring excitement among scientists, and skepticism among vaccine critics. But the accumulating evidence is becoming difficult to dismiss.

New Evidence Strengthens the Case for Shingrix Dementia Prevention

The latest study (Alzheimer’s & Dementia, April 28, 2026) examined adults who received the recombinant zoster vaccine (RZV), sold under the brand name Shingrix. Researchers tracked dementia diagnoses over time and found that vaccinated individuals had a significantly lower likelihood of developing dementia compared to similar adults who remained unvaccinated.

Importantly, the protective effect was not limited to Alzheimer disease. The investigators also reported reductions in vascular dementia, a condition linked to impaired blood flow and inflammation in the brain.

That matters because Alzheimer’s and vascular dementia account for the majority of dementia cases in older adults. I am not going to suggest that Shingrix is a sure-fire solution for preventing cognitive decline. The absolute risk reduction was modest. But the relative risk reduction was surprisingly similar to prior research.

Here is what the authors had to report in their own words:

“Our study found a statistically significant lower risk of new-onset dementia, AD [Alzheimer’s disease], and VD [vascular dementia] with a two-dose RZV [Recombinant Zoster Vaccine=Shingrix] regimen relative to a RZV-unvaccinated comparator, after accounting for the competing risk of death…The 26% to 33% lower risk of dementia following RZV reported in this study corresponds to the results from prior studies that did not distinguish among HZ [herpes zoster] vaccines. Two studies that evaluated HZ vaccines, but did not include RZV [Recombinant Zoster Vaccine=Shingrix], reported HRs [hazard ratios] corresponding to a 22% to 28% lower risk of dementia.”

This new research builds on an increasingly persuasive pattern: shingles vaccination appears to help protect the brain.

Earlier Shingles Vaccine Studies Opened the Door

The first clues came from the older shingles vaccine, Zostavax.

A remarkable “natural experiment” in Wales took advantage of an arbitrary vaccine eligibility cutoff based on birth date. People born just weeks apart were nearly identical—except some qualified for vaccination and others did not. That created an unusually powerful real-world test.

Researchers found that people who got the shingles vaccine were about 20 percent less likely to develop dementia over the next seven years.

Subsequent studies in Australia and Canada found strikingly similar results. When separate populations keep producing the same signal, scientists start paying attention.

Why Might There Be Shingrix Dementia Prevention?

The virus that causes shingles (varicella-zoster) never truly leaves the body. After childhood chickenpox infection, it hides inside nerve cells for decades. Later in life, it can reactivate as shingles.

Some scientists now suspect that viral reactivation may trigger inflammation, blood vessel injury and immune responses that contribute to brain degeneration. That’s one possible explanation for the Shingrix dementia prevention connection.

Another theory involves the vaccine’s immune-stimulating adjuvant. Unlike Zostavax, Shingrix uses a powerful immune activator that may help the body suppress viral reactivation more effectively. That stronger immune response may explain why Shingrix appears to outperform the older vaccine in dementia prevention studies as well as shingles suppression.

Vaccine Skeptics Push Back on Shingrix and Brain Protection

Not everyone is persuaded. Whenever we write about vaccines, we hear from readers who are deeply skeptical. Some insist vaccines cause more harm than good. Others distrust pharmaceutical companies or government recommendations.

We will share some of those comments below because the controversy is real and important. We recognize that some people experience serious harm from vaccines, including the shingles vax.

Don is distrustful:

“It’s interesting that these studies touting the possible and unexpected benefits of certain vaccines in preventing dementia/Alzheimer’s are coming out at a time when vaccine hesitancy/distrust is at all time high. I wonder who is funding the studies?”

Vicki is a victim of a vaccine adverse reaction:

“I know what is in vaccines. NEVER AGAIN! I have studied for more than 30 years after getting MS directly after a vaccine. Got a vaccine, immediately went blind for better than a year (I had 5% sight). I had retro bulbar neuritis which is only MS. It had destroyed my immune system with the vaccine. I do not trust your recommendation. I think you are strictly big pharma paid. I will never take your advice on anything.

“Some years later, my step-grandson who was 3 months old died 3 days after a vaccine. I doubt you will print this.”

Linda reacted badly to the shingles vaccine:

“I got the 2 Shingrix shots in late 2019, the last one days before Christmas. I was immediately ill and had a bad cough that lasted until Feb when I was given some antibiotics. I also developed PVCs after the shots that are still not controlled.

“I was told that no way were the PVCs related to the Shingrix shot, but I never had them before. I was so very sick right after both shots, more so after the second. I was healthy when I got the shots. I researched side effects and saw they only followed patients for 7 days. Never again.”

Charles has every right to feel annoyed about his Shingrix vaccinations:

“I received the first of two Shingrix shots several years ago. About 3 days later, while sitting on the couch, the entire right side of my body, including my foot, which felt like it was turning over on its side, slowly went numb. The numbness started at the injection site. I got up and started doing jumping jacks and my circulation returned.

“I went to the pharmacy, and nothing like this was described in the side effects. I was scheduled to see my primary care physician for a routine visit three days later. He stated that the reaction probably meant I didn’t need the shot. I never felt anything like that since, and I stay up to date on my vaccines at age 73.”

Meri also a bad reaction to the Shingrix shot:

“I had the first dose of Shingrix after the pharmacy where I was working received it from our supplier once it was released. I had such a bad reaction I sent out an email to all the other pharmacists telling them to let patients know that a bad reaction was possible. I was in bed with horrible joint pain, fever and an overwhelming fatigue. It started with the fatigue the day after the shot: I had to leave work early and canceled all my weekend activities.

“From then on I always asked patients if they had any mandatory events in the next 4 days and suggested waiting to get Shingrix until after the event.

“Later the packaging and pharmacist information came out warning of such reactions in 20-30% of patients. I cannot find info on the effectiveness of only one dose and still have not gotten the second shot.”

Kathy warns about a rare reaction that is extremely serious:

“I’d risk shingles over getting Guillian-Barré syndrome with its paralysis any day. My sister got the shot and became paralyzed for weeks. She still has residual nerve pain and limited function.”

Then there is the other side of the vaccine coin:

Tina shares a story about shingles:

“I would encourage anyone on the fence about getting the Shingrix vaccine to seriously consider it. My elderly father had the older shingles vaccine but not the Shingrix vaccine. Two and a half years ago, he had shingles so badly that he was hospitalized twice because the pain was uncontrollable.

“Due to the shingles, he now has post herpetic neuralgia (PHN). Although he takes morphine and gabapentin, the daily pain of PHN is almost unbearable. He often cries out, it is so bad.

“Over the years, his pain management doctor has prescribed other drugs and performed a nerve block, but nothing has helped. He went from being an active man prior to shingles (bowling, volunteering, splitting firewood by hand) to someone who is house bound because of post herpetic neuralgia.”

Marilee shares this story about post herpetic neuralgia:

“I had shingles 6 years ago and remember the pain as if it was yesterday. I also developed postherpetic neuralgia after the rash faded, which lasted for months. There is no real treatment for it other than taking analgesics.

“One doctor suggested I start taking opioids… NO, I did not. NO regrets on that. I just suffered through and it began to fade. I do not want to go through that again. I’m hearing that the shingles shot is effective even if you’ve already had shingles. What amazes me is that Medicare and most private insurance does not help pay for shingles vaccines. That’s just criminal. Shingles seriously debilitates people and can be very harmful depending where on the body it afflicts you, so you’d think insurers would want to prevent it.”

Another reader described her own ordeal:

“I have had shingles on the top of my head, my forehead and inside my eye. It burns with constant, sharp, knife-like pain that goes down through my head and behind my eye. I can’t sleep.”

Challenging the Vaccine Skeptics

The shingles vaccine is like everything else in medicine. There are benefits and there are risks. There is no medicine that does not cause some side effects for some people. Sometimes those side effects can be devastating. Penicillin saves lives, but it can also cause dangerous allergic reactions. No doubt people have died from penicillin because of anaphylactic shock.

I had polio when I was a child. This disease killed a lot of kids. I was in a polio ward where children were dying all around me. Some ended up in iron lungs. It left me with post traumatic stress disorder. I hope that people do not want to see polio return. That would be a consequence of walking away from the vaccine that prevents this deadly disease.

What About Shingrix Dementia Prevention? 

Ask anyone if they would like to protect themselves from dementia or Alzheimer’s disease. Shingrix is not a magic wand. It will not protect everyone. It may only protect a minority of people, but for anyone who has seen dementia up close and personal, any prevention would be welcome.

How do critics explain repeated studies, in different countries and different healthcare systems, all pointing in the same direction? The research suggesting Shingrix dementia prevention doesn’t prove causation. But it does strengthen confidence that this is more than coincidence.

The gold standard would be a randomized controlled trial that tested Shingrix against placebo. It would have to last several years, involve thousands of people and would undoubtedly be very expensive. Since the vaccine is already on the market, it might be hard to convince the pharmaceutical manufacturer to conduct such a clinical trial.

Shingrix Dementia Prevention Could Change Alzheimer Strategy

If these findings hold up, though, the implications are enormous. Current Alzheimer drugs cost tens of thousands of dollars a year and often offer modest benefits.

A shingles vaccine is comparatively inexpensive. And unlike Alzheimer treatments, vaccination happens before damage occurs.

That’s a fundamentally different strategy: preventing the trigger instead of treating the aftermath. If Shingrix truly lowers dementia risk, even modestly, the public health impact could be profound.

Shingrix Still Prevents What It Was Designed to Prevent

Even without the dementia connection, Shingrix remains one of the most effective ways to prevent shingles and postherpetic neuralgia [the lasting pain that can occur after a shingles attack]. Anyone who has suffered nerve pain after shingles knows how devastating that complication can be.

If you took time to read Tina and Marilee’s stories, you have a better idea of how problematic post herpetic neuralgia can be. Preventing that is worth the price of admission.

Watch Our Interview on the Zostavax Vaccine and Dementia

We recently spoke with Pascal Geldsetzer, MD, PhD, MPH, a Stanford physician-scientist whose research helped uncover this surprising connection between shingles vaccination and dementia risk.

Dr. Geldsetzer has analyzed natural experiments in Wales, Australia and Ontario, Canada, and the results have been remarkably consistent.

In this fascinating conversation, he explains:

• how a bureaucratic quirk created a powerful research opportunity
• why viral infections might influence Alzheimer disease
• and why a simple vaccine could potentially reduce dementia risk

Dr. Geldsetzer’s ideas challenge long-held assumptions about Alzheimer disease and open the door to entirely new prevention strategies.

Why Might the Zostavax Vaccine Influence Dementia Risk?

At first glance, the connection between shingles vaccination and dementia sounds improbable. But there are plausible explanations.

When the varicella zoster virus reactivates, it can cause inflammation in the brain and damage small blood vessels. Researchers suspect that this process may trigger a cascade of events that eventually leads to cognitive decline.

Shingles outbreaks may also reactivate other herpes viruses. A Swedish study found that people infected with herpes simplex, the virus responsible for cold sores, were twice as likely to develop dementia over the following 15 years (Journal of Alzheimer’s Disease, Feb. 13, 2024).

The infection-connection theory of AD is not new. More than 40 years ago, pathologist Melvyn J. Ball, MD, proposed that herpes viruses might help trigger Alzheimer disease (Canadian Journal of Neurological Sciences, Aug. 1982). Why neuroscience has mostly ignored Dr. Ball’s research is a mystery to us.

Final Words on Shingrix and Dementia Prevention

For years, Alzheimer researchers chased amyloid. Now the spotlight may be shifting toward infection, inflammation and immunity. That doesn’t mean amyloid is irrelevant. But it may mean we have been looking at only part of the puzzle.

Could protecting against a shingles attack also help protect the brain? The new evidence suggests the answer may be yes. And that’s a question worth taking very seriously.

A study of Kaiser Permanente patients compared people who received the Shingrix vaccine with those who did not. The vaccinated group had a 51 percent lower risk of developing dementia (Nature Communications, Feb. 9, 2026).

Other research suggests shingles vaccination may benefit the heart as well. A massive study of more than one million adults in South Korea found that people who received a shingles vaccine were 25 percent less likely to experience major cardiovascular events, including heart attacks, strokes and heart failure (European Heart Journal, May 5, 2025).

Did you find this article and our video interview with Dr. Geldsetzer of interest?

Please share this article with friends and family. We would be grateful if you let acquaintances know about our work on social media and via email. Every new subscription to our newsletter keeps this website growing. If you can donate to our work, here is a link. Thank you for supporting The People’s Pharmacy!